ASLAN Strikes First Licensing Out Deal For Lead Project
This article was originally published in PharmAsia News
Hyundai Pharm, a mid-sized South Korean pharma firm, is to license in local rights to Singapore venture ASLAN’s lead development molecule varlitinib, a novel small molecule pan-HER inhibitor for cholangiocarcinoma, in a move to boost its oncology pipeline.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.